Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | CurrentPartnering Reports | Partnering with Bigpharma

Partnering with Bigpharma

The Partnering with Bigpharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies. One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies.

A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

Over 200 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities:

* Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues and dealmaking activity since 2005.

* Chapter 3 analyzes the most active dealmakers since 2005 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-8 according to reported deal size.

* Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

* Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

* The main body of the report is provided in chapter 7 and 8.

Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last two years.Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner.

This includes a company overview, detailed analysis of the company's marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area.

Each profile also includes in-depth contact information for individuals within the business development function.In addition, each company profile provides a listing of deal contract documents available in the public domain, each of which links direct to an online copy of the actual contract document as filed with the SEC. One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners' negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms.

Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 1,000 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.

In addition, contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right bigpharma partners effectively and efficiently:

* Detailed company profile for the top 50 bigpharma

* In-depth marketed and pipeline product activity of each company

* Partnering interests and therapy focus revealed

* Partnering activity since 2000 - number of deals per year

* Partnering activity for 2005-2008

* Activity by deal type

* Activity by phase of development

* Activity by therapeutic area

* List of recent partner companies

Direct contact information for over 1,000 bigpharma dealmakers - name, title, email, telephone details, where available

* General company and partnering contact information

* List of contract documents available to allow analysis of bigpharma deal terms - each linked to an online copy of the actual contract as filed at the SEC.

Key benefits

Partnering with Bigpharma provides the user with the following key benefits:

* Detailed company profiles for each of the top 50 bigpharma companies

* Over 200 charts showing a company’s dealmaking activity since 2005, allowing quick identification potential partners

* In-depth marketed and pipeline product activity of each company

* Partnering interests and therapy focus revealed

* Partnering activity since 2000 – number of deals per year

* Partnering activity for 2005-2008

* Activity by deal type

* Activity by phase of development

* Activity by therapeutic area

* List of recent partner companies

* Comprehensive access to over 1,200 actual contracts entered into by the leading fifty biopharma companies

* Insight into the terms included in a partnering agreement, together with real world clause examples

* Understand the key deal terms the company has agreed in previous deals

* Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Partnering with Bigpharma is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.

Partnering with Bigpharma includes:

* Detailed company profiles for each of the top 50 bigpharma companies, including:

* Full contact details

* Business developer contact details including name, title, email and telephone (where available)

* Marketed indications

* Pipeline indications

* Partnering interests and indications

* Partnering activity since 2000

* Current partner companies since 2005

* Partnering activity since 2005 by:

* Deal type

* Stage of development

* Therapy area

* Over 200 charts showing the dealmaking activity of each company since 2005

* The tools to enable effective and efficient preparation for partnering negotiation with bigpharma

* Listing of over 1,200 contract documents between bigpharma and partner companies

* The leading M&A and partnering deals by value 2005-8

* Most active M&A and partnering dealmakers 2005-8

Number of pages: 647 July 2008 Format PDF
Table of Contents
Price: $2,995.00 / €2,001.86

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions